Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
about
Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing OncologistMonoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratificationTP53 Staining in Tissue Samples of Chronic Lymphocytic Lymphoma Cases: An Immunohistochemical Survey of 51 CasesPrognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cellsComparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia.Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemiaPredicting survival in chronic lymphocytic leukemia.Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaChronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaA list of candidate cancer biomarkers for targeted proteomics.A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.RNA-based markers as prognostic factors in chronic lymphocytic leukemia.Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?The role of thymidine kinase in cancer diseases.B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia (CLL)-Then and now.There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.CLINICAL UTILITY OF BETA 2 MICROGLOBULIN MEASUREMENT.Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10(9)/L monoclonal lymphocytes better identifies subgroups with different outcomes.Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*.[Chronic lymphocytic leukemia : treatment concepts in transition].Chronic lymphocytic leukaemia
P2860
Q26775986-095A5FAF-2035-46E0-9CBC-0EA55756F5E7Q28082120-346CFBB4-49E5-43FD-AB53-A8B50C7C60ADQ33747801-E04F2C9B-AA31-4FF0-ABED-212B47E2B84FQ33758834-5511D957-3720-4794-809D-C1F5F65F168FQ33890828-47BED121-E38A-4DEA-A0C8-FC530E6D43D0Q34066000-636345C5-BA25-4CC7-B19F-DBF3CFA6469CQ34179480-6502C4A6-FA96-41E0-A25B-2D807FCE67EDQ34257190-BBDD8483-CFBB-4462-8236-046C9BC4BF7EQ34299723-A5A6B75B-3D8B-484F-9F87-FF7FF636F2E1Q34418874-A75B2502-DAE3-45B9-840B-B1FD09F02DF3Q35461949-736077B0-9885-43BA-8702-7F221D21D426Q35790006-9E17F9D4-DA7F-4FE8-83A1-9B2C7F8035D4Q36292975-62350D73-9FE8-446B-8ABE-AF9ECAE7BAEDQ36743899-80ADD786-8FEF-46B9-977E-DA98A6761E4CQ36826893-946ED3FC-409B-4BFD-8F76-66A36D7237CEQ37257024-19DC0996-E0A9-41BE-AB74-0EE36C1B6CBCQ37277962-86E824AC-CF73-4C12-8C5D-A527FBC48342Q37438957-4974BCE6-6D38-48FE-8B0F-7F99AA527E06Q37615541-CD5C14B3-1713-4827-8D21-75B6DF0564CBQ37978344-61ADBBF5-67B7-4277-8F78-BB18A49BC9EDQ38088354-67140D36-CF19-454F-BE94-C1983AD76F43Q38088840-BD1C4AAD-8624-455A-A4A4-4C353D5B1412Q38611244-CAE413E7-DB24-44FB-B642-318694560A3BQ38675358-47FC6C43-1741-4DD5-950C-1BEB7C845430Q39586919-4CA74908-F43C-4D06-99C8-E0DA215972F2Q40291708-3DD00201-BBC8-4F0D-8579-C48CE4A28073Q42338479-523DFC23-520D-4828-B2AB-7F56ECDE5B34Q44078664-615A6A98-9889-4D83-9C91-592B6585565EQ44929337-507CCBB3-ABAD-4637-BF9C-2BD7574A6BFFQ54536981-06FC61A2-BDC9-442A-AC8D-F9B838369363Q55064971-08C809E5-B012-439E-B504-681B111A1ACAQ56270980-02263563-0FA5-4D8C-908A-E5EBEAA97FB8
P2860
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Serum beta
@nl
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@ast
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@en
type
label
Serum beta
@nl
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@ast
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@en
prefLabel
Serum beta
@nl
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@ast
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@en
P2093
P2860
P1433
P1476
Serum beta(2)-microglobulin an ...... tic leukemia and immunocytoma.
@en
P2093
Emmerich B
Kuhn-Hallek I
Senekowitsch R
P2860
P304
P356
10.3109/10428199609054782
P577
1996-08-01T00:00:00Z